<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082262</url>
  </required_header>
  <id_info>
    <org_study_id>229666-005</org_study_id>
    <nct_id>NCT02082262</nct_id>
  </id_info>
  <brief_title>AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal
      or perennial allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale</measure>
    <time_frame>Baseline, Day 70</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>AGN-229666</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One to two drops of AGN-229666 twice daily in each eye for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-229666</intervention_name>
    <description>One to two drops of AGN-229666 twice daily in each eye for 10 weeks.</description>
    <arm_group_label>AGN-229666</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients living in Japan with allergic conjunctivitis with itching and
             redness

          -  Able and willing to discontinue wearing any contact lenses during the study period.

        Exclusion Criteria:

          -  Eye surgical intervention and/or a history of refractive surgery within 6 months

          -  History of retinal detachment, diabetic retinopathy, or progressive retinal disease

          -  Presence of active eye infection (bacterial, viral, or fungal)

          -  History of an eye herpetic infection

          -  Use of corticosteroids within 6 months or anticipated use during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
